Skip to main content
PharmaResources (Shanghai) Co., Ltd. logo

PharmaResources (Shanghai) Co., Ltd. — Investor Relations & Filings

Ticker · 301230 ISIN · CNE1000065Q9 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 458 across all filing types
Latest filing 2023-04-21 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 301230

About PharmaResources (Shanghai) Co., Ltd.

https://www.pharmaresources.cn

PharmaResources (Shanghai) Co., Ltd. is a comprehensive Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) specializing in small molecule drug discovery and development. The company provides an integrated platform of services including medicinal chemistry, custom synthesis, process research and development, and analytical chemistry. PharmaResources supports global pharmaceutical and biotechnology partners through the entire drug development lifecycle, from initial lead optimization to the commercial-scale manufacturing of advanced intermediates and Active Pharmaceutical Ingredients (APIs). With a focus on technical innovation and quality management, the firm utilizes advanced synthetic methodologies and process engineering to accelerate drug candidates toward clinical trials and market approval.

Recent filings

Filing Released Lang Actions
第三届董事会第七次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on various proposals related to the company's 2022 annual matters, including profit distribution, internal control self-evaluation report, use of raised funds, appointment of auditors, and remuneration plans for directors and senior management. It references compliance with regulatory rules and company bylaws, and it is clearly tied to the company's board meeting and the upcoming 2022 annual shareholders meeting. The document does not contain full financial statements or detailed financial data but rather opinions and approvals on agenda items to be submitted to the shareholders' meeting. This type of document is typically part of board or management information disclosures, especially related to governance and board meeting resolutions. It is not an annual report, audit report, or earnings release. It is not a proxy solicitation or voting results announcement. Given the focus on board meeting matters and independent directors' opinions, the best fitting category is Board/Management Information (MANG). The document length is under 5,000 characters, but it contains substantive content rather than just an announcement of a report publication, so it is not RPA or RNS. Therefore, the classification is MANG with high confidence.
2023-04-21 Chinese
中信证券股份有限公司关于上海泓博智源医药股份有限公司首次公开发行股票募投项目延期事项的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from CITIC Securities regarding the delay in the use of funds raised from the initial public offering (IPO) of Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. It discusses the fundraising amount, usage progress, reasons for project delay, and approvals from the board, supervisory committee, and independent directors. It references regulatory guidelines and confirms compliance with relevant securities regulations. The document is not a full financial report but a regulatory compliance and verification statement related to the use of IPO proceeds and project delays. It does not contain financial statements or earnings data, nor is it a simple announcement of a report. This fits best under Regulatory Filings (RNS), which covers compliance documents and miscellaneous filings that do not fit other categories.
2023-04-21 Chinese
立信会计师事务所(特殊普通合伙) 关于上海泓博智源医药股份有限公司2022年度募集资金存放与使用情况专项报告的鉴证报告
Audit Report / Information Classification · 95% confidence The document is a detailed report on the use and management of funds raised by Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. in 2022. It references compliance with the China Securities Regulatory Commission's guidelines on the management and use of raised funds, includes audited verification by an accounting firm, and provides detailed tables on the amounts raised, used, and remaining. The document is titled as a "募集资金存放与使用情况专项报告" which translates to a "Special Report on the Storage and Use of Raised Funds." This type of report is a specialized audit or assurance report focusing on the use of capital raised by the company, not a full annual report or earnings release. It is not a mere announcement or certification but contains substantive financial and compliance information related to fundraising. Therefore, it fits best under the category of Audit Report / Information (AR), which includes standalone audit reports and applied accounting principles related to specific financial matters such as fundraising usage. FY 2022
2023-04-21 Chinese
2022年度董事会工作报告
Board/Management Information Classification · 95% confidence The document is titled as the "2022 Annual Board of Directors Work Report" of Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. It details the board's activities, company performance, meeting summaries, resolutions passed, governance practices, and plans for 2023. The content focuses on the board's work and governance rather than full financial statements or audit opinions. It includes detailed descriptions of board meetings, resolutions, and governance improvements, which aligns with a Board/Management Information report. The document length is 4678 characters, which is sufficient for a detailed report but not a full annual report or audit report. There is no indication that this is a call transcript, earnings release, or other categories. Therefore, the best fit is Board/Management Information (MANG).
2023-04-21 Chinese
关于会计政策变更的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding changes in accounting policies by Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. It references specific accounting standards and interpretations issued by the Ministry of Finance of China, detailing the nature and impact of these changes. The document does not contain full financial statements or comprehensive financial performance data but rather explains the policy changes and their effects. The length is 4384 characters, which is relatively short and focused on policy change disclosure. This fits the category of a Regulatory Filing (RNS) as it is a compliance announcement about accounting policy changes without being a full annual or interim report or audit report.
2023-04-21 Chinese
2022年年度报告
Annual Report Classification · 100% confidence The document is titled "上海泓博智源医药股份有限公司2022 年年度报告全文" which translates to "Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. 2022 Annual Report Full Text." It includes detailed sections such as company overview, financial data, management discussion and analysis, corporate governance, environmental and social responsibility, important matters, shareholder information, bond information, and the financial report. The document contains comprehensive financial data, management analysis, and detailed business descriptions for the fiscal year 2022. The length is substantial (15,000 characters), and it is clearly the full annual report, not just an announcement or summary. Therefore, it fits the definition of an Annual Report (10-K). FY 2022
2023-04-21 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.